|Year : 2021 | Volume
| Issue : 4 | Page : 367-372
Evaluation of the antidiabetic potential of an isolated hydroalcoholic fraction from the fruit of withania coagulans
Md Waris1, Naiyer Shahzad2, Saeed Saeed Al-Ghamdi2, Showkat Rasool Mir3, Tanuja1
1 Department of Botany, Thakur Prasad Singh (TPS) College, Patna, Magadh University, Bodh Gaya; Department of Botany, Thakur Prasad Singh (TPS) College, Patliputra University, Patna, Bihar, India
2 Department of Pharmacology and Toxicology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
3 Department of Pharmacognosy and Phytochemistry, Phytopharmaceutical Research Laboratory, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India
|Date of Submission||12-Jul-2020|
|Date of Decision||05-Aug-2020|
|Date of Acceptance||20-Oct-2020|
|Date of Web Publication||04-Mar-2022|
Department of Botany, Thakur Prasad Singh (TPS) College, Patliputra University, Patna - 800 001, Bihar
Source of Support: None, Conflict of Interest: None
| Abstract|| |
The hydro-alcoholic extract of Withania coagulans fruits was investigated for preliminary phytochemical screening and characterized by high-performance thin-layer chromatography. Column chromatography of the hydro-alcoholic extract of W. coagulans eluted with four different combinations of ethyl acetate and methanol yielded four fractions (WCF01, WCF02, WCF03, and WCF04). One of these fractions, WCF02, significantly (P < 0.05) inhibited in vitro α-amylase and α-glucosidase activity with IC50 values of 104.71 μg/mL and 70.79 μg/mL, respectively. WCF02 further reduced blood glucose levels in comparison to control in the starch tolerance test. The extract showed a relative dose-dependent effect. It was observed that none of the extracts could delay the peak blood glucose that was achieved after 60 min of carbohydrate challenge, but these blunted the glycemic peak.
Keywords: Glycemia, high-performance thin-layer chromatography, hydro-alcoholic, Withania coagulans, α-amylase, α-glucosidase
|How to cite this article:|
Waris M, Shahzad N, Al-Ghamdi SS, Mir SR, Tanuja. Evaluation of the antidiabetic potential of an isolated hydroalcoholic fraction from the fruit of withania coagulans. J Pharm Bioall Sci 2021;13:367-72
|How to cite this URL:|
Waris M, Shahzad N, Al-Ghamdi SS, Mir SR, Tanuja. Evaluation of the antidiabetic potential of an isolated hydroalcoholic fraction from the fruit of withania coagulans. J Pharm Bioall Sci [serial online] 2021 [cited 2022 Oct 1];13:367-72. Available from: https://www.jpbsonline.org/text.asp?2021/13/4/367/339086
| Introduction|| |
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by hyperglycemia resulting from insufficient insulin secretion, ineffective insulin action, or both. It has been referred to as pandemic as more than 400 million cases of DM prevailed across the globe by 2014, accounting for 1.6 million deaths in 2016. Type 2 DM covers the major diabetic populations around the world and mostly attributed to excess body weight (body mass index >30) and decreased physical activities. It has been always related to long-term complications such as retinopathy, neuropathy, nephropathy, atherosclerosis, and cataracts, which make it one of the leading causes of blindness, acute and chronic renal failure, lower-extremity amputations, vision loss, and neuronal pathologies. Diabetic complications lead to the risk of myocardial infarction and stroke and are thus largely responsible for the mortality observed in these patients.,,,, Diet and exercises are crucial in healthy maintenance of the blood glucose levels and thus preventing and treating Type 2 diabetes. The majority of diets contain carbohydrates which are the greatest source of calories. Dietary polysaccharides are broken down by digestive enzymes such as α-amylase which is chiefly present in pancreatic juice and saliva that randomly cleaves α (1 → 4) glycosidic linkages and intestinal α-glucosidase that hydrolyzes the terminal nonreducing (1 → 4)-linked alpha-glucose residues.,,, Thus, α-amylase and α-glucosidase are regarded as good targets for antidiabetic agents and their inhibition is one of the important ways to control postprandial hyperglycemia in Type 2 diabetics by delaying carbohydrate digestion to absorbable monosaccharide. Acarbose and voglibose are clinically used α-glucosidase inhibitors which potentially reduce the DM complications., Though different α-glucosidase inhibitors are available as oral hypoglycemic agents for the management of Type 2 diabetes, there is an increased patient demand of natural products with blood glucose-lowering activity. Ethnobotanical use has a long history in Type 2 DM management. A large number of plants and their products have been reported to possess α-amylase and α-glucosidase inhibitory activities.,,,,,,, W. coagulans fruits, commonly known as Indian rennet, are distributed in drier parts of India. The fruits are superior indehiscent, many-seeded berries, round to globous in shape, yellow to brown in color enclosed in the leathery persistent calyx, and the fruit decoction has been recommended to be taken in the morning or before meals for glycemic control in diabetic patients. Withanolides from different parts of the plant has been reported for diverse biological activities such as antimicrobial, anthelmintic, oxidative stress and anti-inflammatory, antitumor, hepatoprotective, antispasmodic, antihyperlipidemic, antidiabetic activity,, and wound healing in diabetic rats. There is no safe and effective therapy in modern medicine to cure DM. Insulin therapy has many adverse effects such as insulin resistance, fatty liver, brain atrophy and anorexia nervosa. To the best of our knowledge, this is the first work on the hydroalcoholic extract of W. coagulans fruits and methanol-ethyl acetate fraction. Although W. coagulans fruit extracts have been described to possess anti-diabetic activity, the compounds responsible for this hypoglycemic activity remain unknown. Therefore, the present work was planned to carry out phytochemical screening of W. coagulans fruits and investigate in vitro and in vivo antidiabetic potentials of W. coagulans fruits.
| Experimental Methods|| |
W. coagulans fruits were procured from the Hansraj and Sons, Khari Baoli, local crude drug market of Delhi, and authenticated by Dr. Sunita Garg, Emeritus Scientist and Taxonomist, CSIR-NISCAIR, New Delhi-12, and the sample specimen (authentication no. NISCAIR/RHMD/Consult/2019/3423-24) was deposited in the Raw Material Herbarium and Museum, Delhi (RHMD), for future references. The samples were stored at room temperature.
Chemical and reagents
All the supplies, chemicals, and reagents of analytical grade were received from SD Fine chemicals & glass ware in Mumbai, Maharashtra (Retailer of Merck Chemicals). Column drying was carried out by using anhydrous sodium sulfate. Pancreatic α-amylase (porcine; Type VI-B; A3176), α-glucosidase (Type I from baker's yeast) G5003, 3,5-dinitrosalicylic acid (DNS), starch (85642), and acarbose (C25H43NO18, molecular weight 645; A8980) were supplied from Sigma Aldrich (St. Louis, USA).
Air-dried W. coagulans fruit (3 kg) was crushed to get the coarse powder and defatted with hexane by refluxing it for approximately 48 h to remove waxy material. After defatting, the sample was completely dried to remove any traces of hexane. The sample was then packed in a Soxhlet apparatus with hydroalcoholic solvent (methanol: water, 90:10), and extraction was continued until the color of the siphoning tube disappeared. The extract was then collected and concentrated under reduced pressure to yield a dark brown viscous syrupy mass (23.5% yield).
Hydrolysis of extract and its preliminary analysis
The hydroalcoholic extract (10 g) was mixed with a small amount of 2 N hydrochloric acid to get the final pH of 3.5 and the mixture was refluxed for 3–4 h to completely hydrolyze the extract. The mixture was put on crushed ice with stirring and allowed to attain room temperature. The preliminary phytochemical screening was carried out to check the presence of primary/secondary metabolites in the biologically active extract of the crude drug.,,
High-performance thin-layer chromatography procedure
A precoated silica gel (high-performance thin-layer chromatography [HPTLC] 60 F254) was used to carry out HPTLC and chromatography in a presaturated developing chamber (20 mL of 80:20:12, v/v/v ethyl acetate–methanol–water) for 30 min at 50% ± 5% relative humidity and room temperature.
The sample was prepared by diluting hydroalcoholic extract (100 mg) with methanol (10 mL) and sonicating at 50°C ± 2°C for 15 min. It was filtered through 0.2-μ filter paper, diluted further to prepare test solutions, and applied by a thin-layer chromatography (TLC) auto sampler on 6-mm wide bands on plate. There was a 9-cm long chromatogram from the base. TLC plate was dried under hot air in oven and the bands were visualized under Camag Scanner video documentation system (Camag Muttenz, Switzerland).
Isolation of fractions from extract
To prepare the slurry, the solution was made by dissolving hydroalcoholic extract of dark brown syrupy mass (100 g) in sufficient amount of methanol and absorbed on 60–120 mesh size silica gel. The development and elution were carried out with sequential solvents in different proportions of ethyl acetate: methanol (95:5, 90:10, 85:15, and 80:20 v/v). Homogeneity of various fractions collected was checked through TLC. Identical fractions of the extract were combined and pooled and kept for crystallization.
In vitro α-amylase inhibition study
A volume of 1 mL of each fraction of hydroalcoholic extract and 1.2 mL of porcine α-amylase of 0.5% concentration in 20 mM phosphate buffer were mixed and put for 10 min of incubation at 25°C. Afterward, 1.2 mL of starch solution (0.5% w/v) in 20 mM phosphate buffer (pH 7) was added to the reaction mixture, and then further incubated for another 10 min. The reaction was then stopped with 2 mL of 96 mM DNS. Then, the test tubes were heated for 5 min in a boiling water bath and left to cool to room temperature. The absorbance (A) of samples was taken at 540 nm using Amersham Biosciences spectrophotometer (Buckinghamshire, United Kingdom). The inhibitory enzyme activity was calculated in percentage as
where is the absorbance of control sample without extract at 540 nm, and is the absorbance of treatment with extract at 540 nm.
In vitro α-glucosidase inhibition study
A volume of 100 μl of each fraction of hydroalcoholic extract was diluted with phosphate buffer (pH 7) solution and incubated for 5 min with 50 μL (1 U/mL) of α-glucosidase. After the incubation, 50 μL of the substrate was added and incubated further for 5 min at room temperature. The absorbance on a microplate reader after substrate addition was taken at 405 nm. Increased absorbance after a substrate addition was observed and percent α-glucosidase inhibition was calculated as:
where is the absorbance of control sample without extract at 405 nm and is the absorbance of treatment with extract at 405 nm.
In vivo oral starch tolerance test
Eight- to ten-week-old Swiss albino mice (Mus musculus) weighing in the range of 25 ± 2 g were used in the present study. The animals were brought from the animal house facility of Rajendra Memorial Research Institute of Medical Sciences, Patna. They were segregated into five groups each consisting of six mice (n = 6). The animals were subjected to free access of water and fasted overnight. Group 1 was given 4 mL/kg (normal control) distilled water orally using oral gavage, Group 2 was given acarbose 10 mg/kg body weight (positive control/standard), treatment Group 3 was subjected to 500 mg/kg b/w of 20% (v/v) hydroalcoholic extract of W. coagulans (D1), Group 4 received 750 mg/kg of 20% (v/v) hydroalcoholic extract of W. coagulans (D2), and treatment Group 5 was treated orally 1000 mg/kg of 20% (v/v) hydroalcoholic extract of W. coagulans (D3). Ten minutes later, all the mice were given starch solution (3 g/kg body weight) orally and the blood glucose was estimated before and after starch administration at 0 min and at 30, 60, 90, and 120 min. All the experimental procedures were approved by the Institutional Animal Ethics Committee, S.S. Hospital and Research Institute, in collaboration with Department of Botany, Thakur Prasad Singh College, Patna (Magadh University), Bodh Gaya (India) vide letter no. 1840/PO/ReBi/S/15/CPCSEA.
Experiments were performed in triplicate. Data were presented as mean, standard deviation, and standard error of mean (SEM). The inhibitory concentration (IC50) of extracts was obtained by nonlinear regression using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA). IC50 values were expressed as mean. Oral starch test data were reported as mean ± SEM. One-way ANOVA followed by Dunnett's multiple comparison t-test determined statistical significance at P < 0.05.
| Results|| |
Extraction and preliminary analysis
Extraction of W. coagulans fruit with hydroalcoholic solvent (methanol: water, 90:10) yielded a dark brown viscous syrupy mass 690 g (23.5% yield). A portion of this extract was analyzed for the presence of alkaloids, glycosides, phenolic compounds, tannins, flavonoids, saponins, and mucilage, etc., [Table 1].
|Table 1: Phytochemical screening of hydroalcoholic extract of Withania coagulans Dunal fruits|
Click here to view
High-performance thin-layer chromatography study of hydroalcoholic extract
HPTLC of the hydroalcoholic extract of W. coagulans at different dilutions exhibited a number of bands when visualized with CAMAG HPTLC scanner IV. The developed plate was scanned at a wavelength of 372 nm for the densitometric measurements. A close examination of peaks revealed that nearly 11 fractions were present in the hydroalcoholic extract of W. coagulans fruit [Figure 1]. Chromatograms showed a number of peaks with different Rf values [Figure 2].
|Figure 1: Chromatogram (two dimensional), densitometric measurements of hydroalcoholic extract scanned at wavelength 372 nm. Peaks shows nearly 11 fractions of the hydroalcoholic extract of Withania coagulans fruit|
Click here to view
|Figure 2: Chromatogram (three-dimensional), densitometric measurements of hydroalcoholic extract scanned at wavelength 372 nm|
Click here to view
Isolation of fractions from extract
Four different combinations of ethyl acetate: methanol (95:5, 90:10, 85:15, and 80:20 v/v) were used as eluent, and development of chromatogram gave four fractions (WCF01, WCF02, WCF03, and WCF04). The concentration of these fractions under reduced pressure yielded crystals of different color and melting points. These fractions were evaluated for their antidiabetic potential.
The antidiabetic activities were assessed in vitro and in vivo for four different fractions (WCF01, WCF02, WCF03, and WCF04) of hydroalcoholic extract of W. coagulans.
In vitro α-amylase inhibition study
Different fractions (WCF01, WCF02, WCF03, and WCF04) of hydroalcoholic extract of W. coagulans fruit were used for the α-amylase inhibition study. Each of these fractions was studied for in vitro α-amylase inhibition study for four different twofold concentrations (100 μg/mL, 200 μg/mL, 400 μg/mL, and 800 μg/mL) as per the standard procedure. One fraction (WCF02) of hydro-alcoholic extract of W. coagulans showed statistically significant (P < 0.05) enzyme inhibition compared to other fractions. The inhibition varied from 37.81% to 68.36% in the case of WCF01, 47.30%–97.48% for WCF02, 18.24%–38.72% for WCF03, and 23.03%–53.94% for WCF04 [Table 2]. α-amylase inhibition was dose dependent for all the fractions. The IC50 values for α-amylase inhibition were 269.15 μg/ml for WCF01, 104.71 μg/ml for WCF02, 1528.64 μg/ml for WCF03, and 616.50 μg/ml for WCF04 [Table 2].
|Table 2: α-amylase inhibition studies of various fractions of hydroalcoholic extract of Withania coagulans Dunal fruits|
Click here to view
In vitro α-glucosidase inhibition study
Different fractions (WCF01, WCF02, WCF03, and WCF04) of hydroalcoholic extract of W. coagulans fruit were used for the α-glucosidase inhibition study. Each of these fractions was studied for in vitro α-glucosidase inhibition study for four different twofold concentrations (100 μg/mL, 200 μg/mL, 400 μg/mL, and 800 μg/mL) as per the standard procedure.
One of the fractions (WCF02) of hydroalcoholic extract of W. coagulans showed statistically significant (P < 0.05) inhibition compared to other fractions. The inhibition varied from 39.81% to 68.36% for WCF01, 57.30%–98.48% for WCF02, 27.32%–58.18% for WCF03, and 33.13%–53.94% for WCF04. Moreover, all the fractions showed a relatively dose-dependent inhibition of α-glucosidase activity [Table 3]. The IC50 values for α-glucosidase inhibition were 177.82 μg/mL for WCF01, 70.79 μg/mL for WCF02, 447.66 μg/mL for WCF03, and 645.69 μg/mL for WCF04 [Table 3].
|Table 3: α-glucosidase inhibition studies of various fractions of hydroalcoholic extract of Withania coagulans Dunal fruits|
Click here to view
In vivo oral starch tolerance test
The fractions obtained from W. coagulans fruit extract showed a significant enzymatic inhibition in vitro experiment was thus subjected to in vivo studies. The oral carbohydrate challenge in Swiss albino mice was carried out with starch (3 g/kg) after pretreatment with different concentrations of WCF02. The WCF02 fraction was tested at three different doses of 500 mg/kg (D1), 750 mg/kg (D2), and 1000 mg/kg (D3) compared with standard (acarbose 10 mg/kg) and normal control. In all the animals, the blood glucose concentration was recorded. The group treated at lower doses D1 and D2 [Table 4] did not show significant effect till 90 min. However, D3 extract of W. coagulans showed significant reduction against starch control mice at 90 and 120 min.
|Table 4: Oral starch tolerance test in Swiss albino mice with different concentrations of WCF02|
Click here to view
| Discussion|| |
DM is a long-term serious complication with the major impact on individuals, families, and the societies and their lives. It is one of the top ten causes of adult death globally. This study was intended to examine the antidiabetic potential of W. coagulans fruit extract using in vitro and in vivo tests. The extract tested positive for the presence of alkaloids, glycosides, phenolic compounds, tannins, flavonoids, saponins, resins, and mucilage. Many studies of W. coagulans extract from different parts of the plant reported the similar active compounds. Because DM is a complex disease involving multiple factors, different models were used. Commonly, studies of natural products for prevention of DM primarily focused on to investigate the inhibition of α-glucosidase that hydrolyzes starch/disaccharides to glucose. The partial inhibition of α-amylase is rate limiting and thus α-amylase inhibition decreases the glucose release from starch. Inhibition of α-amylase activity by W. coagulans leaf extract is reported in literature that suggests a possible causal relationship between the bioactive component and enzyme inhibition. In the present study, all the fractions showed a relatively dose-dependent decrease in α-amylase activity. The IC50 values for α-amylase inhibition were 269.15 μg/mL for WCF01, 104.71 μg/mL for WCF02, 1528.64 μg/mL for WCF03, and 616.50 μg/ml for WCF04. Thus, the results of the present study of α-amylase inhibition are in agreement with the results of Heo et al. Polyphenolic components from plants,, have been recently reported to be efficient α-amylase inhibitors.,, α-glucosidase is the source of hydrogen in catalytic hydrolysis of α-(1,4)-glucosidic link, and hydrogen scavenging is the primary mechanism of α-glucosidase inhibition by polyphenols. Therefore, it is expected that polyphenols and withanolides are responsible for α-glucosidase inhibition. Complexation is supposed to be the principal mechanism of α-amylase inhibition that delays the carbohydrate digestion and decrease glucose absorption., Most of the pharmacological studies have shown that the biological properties of Withania are due to withanolides and polyphenols. The present study showed α-amylase and α-glucosidase inhibition by hydroalcoholic extract of W. coagulans.
| Conclusion|| |
Hydroalcoholic extract of W. coagulans fruits showed significant α-amylase and α-glucosidase inhibition in vitro. The oral starch tolerance test also showed a significant reduction in blood glucose level. On the basis of the result obtained, it is established that W. coagulans fruit extract possess antidiabetic properties. The underlying inhibitory action of W. coagulans fruit extract on α-amylase and α-glucosidase is the delayed digestion and decreased gut carbohydrate absorption. It is further postulated that a prolonged pretreatment for 20–30 min before carbohydrate overload may result in better glycemic control. Hence, further investigations shall be carried out to explore the principal bioactive components of the extract and their antidiabetic effect.
We are highly thankful to the department members, laboratory staffs, and our associates assisted throughout the complete research work.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Shukla K, Dikshit P, Shukla R, Gambhir JK. The aqueous extract of Withania coagulans
fruit partially reverses nicotinamide/streptozotocin-induced diabetes mellitus in rats. J Med Food 2012;15:718-25.
Ojha S, Alkaabi J, Amir N, Sheikh A, Agil A, Fahim MA, et al. Withania coagulans
fruit extract reduces oxidative stress and inflammation in kidneys of streptozotocin-induced diabetic rats. Oxid Med Cell Longev. 2014;2014:1-9.
Bhutani J, Bhutani S. Worldwide burden of diabetes. Indian J Endocrinol Metab 2014;18:868-70.
Liu M, Liu SW, Wang LJ, Bai YM, Zeng XY, Guo HB, et al
. Burden of diabetes, hyperglycaemia in China from to 2016: Findings from the 1990 to 2016, global burden of disease study. Diabetes Metab 2019;45:286-93.
Kador PF, Kinoshita JH, Sharpless NE. Aldose reductase inhibitors: A potential new class of agents for the pharmacological control of certain diabetic complications. J Med Chem 1985;28:841-9.
Porte D Jr., Schwartz MW. Diabetes complications: Why is glucose potentially toxic? Science 1996;272:699-700.
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20.
Suzen S, Buyukbingol E. Recent studies of aldose reductase enzyme inhibition for diabetic complications. Curr Med Chem 2003;10:1329-52.
Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: A review of current evidence. Diabetologia. 2019;62:3-16.
Barrett ML, Udani JK. A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris
): A review of clinical studies on weight loss and glycemic control. Nutr J 2011;10:1-10.
Adisakwattana S, Jiphimai P, Prutanopajai P, Chanathong B, Sapwarobol S, Ariyapitipan T. Evaluation of alpha-glucosidase, alpha-amylase and protein glycation inhibitory activities of edible plants. Int J Food Sci Nutr 2010;61:295-305.
Bashary R, Vyas M, Nayak SK, Suttee A, Verma S, Narang R, et al
. An insight of alpha-amylase inhibitors as a valuable tool in the management of type 2 diabetes mellitus. Curr Diabetes Rev 2020;16:117-36.
Maurya R, Akanksha, Jayendra, Singh AB, Srivastava AK. Coagulanolide, a withanolide from Withania coagulans
fruits and antihyperglycemic activity. Bioorg Med Chem Lett 2008;18:6534-7.
Yadav JP, Saini S, Kalia AN, Dangi AS. Hypoglycemic and hypolipidemic activity of ethanolic extract of Salvadora oleoides
in normal and alloxan-induced diabetic rats. Indian J Pharmacol 2008;40:23-7.
] [Full text]
Tran TN, Doan CT, Nguyen VB, Nguyen AD, Wang SL. Anti-oxidant and anti-diabetes potential of water-soluble chitosan-glucose derivatives produced by maillard reaction. Polymers (Basel) 2019;11:1-13.
Sun H, Wang D, Song X, Zhang Y, Ding W, Peng X, et al
. Natural prenylchalconaringenins and prenylnaringenins as antidiabetic agents: α-glucosidase and α-amylase inhibition and in vivo
antihyperglycemic and antihyperlipidemic effects. J Agric Food Chem 2017;65:1574-81.
Rasouli H, Hosseini-Ghazvini SM, Adibi H, Khodarahmi R. Differential α-amylase/α-glucosidase inhibitory activities of plant-derived phenolic compounds: A virtual screening perspective for the treatment of obesity and diabetes. Food Funct 2017;8:1942-54.
Heo SJ, Hwang JY, Choi JI, Han JS, Kim HJ, Jeon YJ. Diphlorethohydroxycarmalol isolated from Ishige okamurae, a brown algae, a potent alpha-glucosidase and alpha-amylase inhibitor, alleviates postprandial hyperglycemia in diabetic mice. Eur J Pharmacol 2009;615:252-6.
Subramanian R, Asmawi MZ, Sadikun A. In vitro
alpha-glucosidase and alpha-amylase enzyme inhibitory effects of Andrographis paniculata
extract and andrographolide. Acta Biochim Pol 2008;55:391-8.
Poovitha S, Parani M. In vitro
and in vivo
α-amylase and α-glucosidase inhibiting activities of the protein extracts from two varieties of bitter gourd (Momordica charantia
L.). BMC Complement Altern Med 2016;16 Suppl 1:1-8.
Datta A, Bagchi C, Das S, Mitra A, Pati AD, Tripathi SK. Antidiabetic and antihyperlipidemic activity of hydroalcoholic extract of Withania coagulans
Dunal dried fruit in experimental rat models. J Ayurveda Integr Med 2013;4:99-106.
] [Full text]
Prasad SK, Kumar R, Patel DK, Hemalatha S. Wound healing activity of Withania coagulans
in streptozotocin-induced diabetic rats. Pharm Biol 2010;48:1397-404.
Herborne J. Phytochemical Methods. A Guide to Modern Techniques of Plant Analysis. Netherlands:Springer; 1973. p. 5-11.
Harbon J. Phytochemical Methods: A Guide to Modern Techniques of Plant Analysis. New York: Chapman and Hall Int.; 1998. p. 488-93.
Singleton VL, Orthofer R, Lamuela-Raventós RM.
Analysis of total phenols and other oxidation substrates and antioxidants by means of Folin–Ciocalteu reagent. In: Methods in Enzymology. Vol. 299. United States: Academic Press; 1999. p. 152-78.
Miller GL. Use of dinitrosalicylic acid reagent for determination of reducing sugar. Anal Chem 1959;31:426-8.
de Melo EB, da Silveira Gomes A, Carvalho I. α- and β-Glucosidase inhibitors: Chemical structure and biological activity. Tetrahedron 2006;62:10277-302.
Nahoum V, Roux G, Anton V, Rougé P, Puigserver A, Bischoff H, et al
. Crystal structures of human pancreatic α-amylase in complex with carbohydrate and proteinaceous inhibitors. Biochem J 2000;346:201-8.
[Figure 1], [Figure 2]
[Table 1], [Table 2], [Table 3], [Table 4]